Valneva SE (VALN) Cash from Investing Activities (2021 - 2026)
Valneva SE (VALN) posted quarterly Cash from Investing Activities of $312937.4 for Q1 2026, up 128.62% year-on-year from $136883.4 in Q1 2025, and up 204.17% on a QoQ basis from -$300419.9 in Q4 2025.
Valneva SE (VALN) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Cash from Investing Activities for 6 consecutive years, with $312937.4 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities rose 128.62% year-over-year to $312937.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$538252.4 (up 95.6% YoY) and the FY2025 annual result came in at -$1.9 million, down 102.22% from the prior year.
- Cash from Investing Activities grew to $312937.4 in Q1 2026 per VALN's latest filing, from -$300419.9 in the prior quarter.
- Over the last five years, Cash from Investing Activities for VALN reached as high as $7.5 billion in Q3 2023 and fell as low as -$7.5 billion in Q2 2023.
- A 5-year average of $1.7 million and a median of -$1.1 million in 2025 frame the typical range for Cash from Investing Activities.
- The largest YoY upside for Cash from Investing Activities was 102222.53% in 2023 against a maximum downside of 101128.64% in 2023.
- Year by year, Cash from Investing Activities stood at -$7.5 million in 2022, then slumped by 148.3% to -$18.6 million in 2023, then surged by 128.73% to $5.3 million in 2024, then plunged by 105.63% to -$300419.9 in 2025, then surged by 204.17% to $312937.4 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $312937.4, -$300419.9, and $224177.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Valneva SE | 839.18 Mn | 719.39 Mn | 5.38 Mn | 312,937.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 312,937.42 |
| Mar 31, 2026 | 312,937.42 |
| Dec 31, 2025 | -300,419.93 |
| Dec 31, 2025 | -300,419.93 |
| Sep 30, 2025 | 224,176.99 |
| Sep 30, 2025 | 224,176.99 |
| Jun 30, 2025 | -774,946.86 |
| Jun 30, 2025 | -774,946.86 |
| Mar 31, 2025 | -1.09 Mn |
| Mar 31, 2025 | -1.09 Mn |
| Dec 31, 2024 | 5.33 Mn |
| Dec 31, 2024 | 5.33 Mn |
| Sep 30, 2024 | -17.50 Mn |
| Sep 30, 2024 | -17.50 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 98.68 Mn |
| Mar 31, 2024 | 98.68 Mn |
| Dec 31, 2023 | -18.57 Mn |
| Dec 31, 2023 | -18.57 Mn |